StreetInsider.com News Articles

Avita Medical Ltd. (RCEL) PT Raised to $12 at Lake Street

Fri, 28 Aug 2026 09:24:57 -0400

Lake Street analyst Frank Takkinen raised the price target on Avita Medical Ltd. (NASDAQ: RCEL) to $12.00 (from $8.00) while maintaining a Buy rating.

Avita Medical Limited (RCEL) 1600 contracts of October 15 calls trade, share price up 6.4%

Tue, 25 Aug 2026 15:18:54 -0400

Avita Medical Limited (NASDAQ: RCEL) 30-day option implied volatility is at 70; compared to its 52-week of 58 to 133 with a focus on 1600 contracts of October 15 calls as share price up 6.4%.

Form S-8 AVITA Medical, Inc.

Tue, 25 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260825/26971729.html

Form S-8 AVITA Medical, Inc.

Tue, 25 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260825/26971729.html

Form S-8 AVITA Medical, Inc.

Tue, 25 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260825/26971729.html

Form 4/A AVITA Medical, Inc. For: Jun 12 Filed by: O'Toole David D

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968976.html

Form 4/A AVITA Medical, Inc. For: Jun 12 Filed by: O'Toole David D

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968976.html

Avita Medical Ltd. (RCEL) PT Raised to $14 at TD Cowen

Wed, 19 Aug 2026 09:13:35 -0400

(Updated - August 19, 2026 9:13 AM EDT)

TD Cowen analyst Joshua Jennings raised the price target on Avita Medical Ltd. (NASDAQ: RCEL) to $14.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "KOL Webinar Increases Our Confidence In PermeaDerm's Commercial Potential; Avita hosted a KOL webinar to discuss PermeaDerm I clinical trial data, which showed a clear economic benefit vs. allograft with comparable clinical outcomes. Overall, the KOL discussion further reinforced our view that the new clinical data should catalyze stronger PermeaDerm adoption trends; we believe PermeaDerm represents an essential component of Avita's burncare ecosystem. Reiterate Buy. Following this

Avita Medical Ltd. (RCEL) PT Raised to $14 at TD Cowen

Wed, 19 Aug 2026 09:13:35 -0400

(Updated - August 19, 2026 9:13 AM EDT)

TD Cowen analyst Joshua Jennings raised the price target on Avita Medical Ltd. (NASDAQ: RCEL) to $14.00 (from $12.00) while maintaining a Buy rating.

Avita Medical Ltd. (RCEL) PT Raised to $11 at BTIG

Wed, 19 Aug 2026 05:48:28 -0400

BTIG analyst Ryan Zimmerman raised the price target on Avita Medical Ltd. (NASDAQ: RCEL) to $11.00 (from $7.00) while maintaining a Buy rating.

The analyst comments "RCEL announced positive results from its PermeaDerm-I study, which met its primary endpoint. Results demonstrated a statistically significant (p<0.001) 70% economic advantage over allograft based on product cost per percent TBSA treated as well as a 96% reduction in preparation time and comparable clinical outcomes. In conjunction with the positive data, RCEL also hosted a KOL event, highlighting PermeaDerm's real-world utility as a clinically predictable, easy-to-use alternative to allograft and its role as the entry

Avita Medical Ltd. (RCEL) PT Raised to $11 at BTIG

Wed, 19 Aug 2026 05:48:28 -0400

BTIG analyst Ryan Zimmerman raised the price target on Avita Medical Ltd. (NASDAQ: RCEL) to $11.00 (from $7.00) while maintaining a Buy rating.

AVITA Medical study shows PermeaDerm costs 70% less than allograft

Tue, 18 Aug 2026 07:45:47 -0400

AVITA Medical, Inc. (NASDAQ: RCEL) announced results from its multicenter, randomized controlled PermeaDerm-I clinical study, showing that PermeaDerm, a biosynthetic wound matrix, achieved comparable clinical outcomes to cadaveric allograft at 70% lower product cost.

The study met its primary endpoint with statistical significance (p<0.001). Mean treatment cost was $148.70 per 1% total body surface area (%TBSA) treated with PermeaDerm, compared with $497.10 for allograft, representing a savings of approximately $348 per %TBSA.

The trial enrolled 40 patients across 11 U.S. burn centers with wounds involving up to 30% TBSA. Patients were randomized following surgical excision to receive either PermeaDerm or cadaveric allograft

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

Form 8-K AVITA Medical, Inc. For: Aug 05

Tue, 11 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26906312.html

Form 8-K AVITA Medical, Inc. For: Aug 05

Tue, 11 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26906312.html

Form 8-K AVITA Medical, Inc. For: Aug 05

Tue, 11 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26906312.html

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, at 9:00 a.m. Australian Eastern Standard Time).

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are